

argenx SE 2022 benchmark peer group

Selection criteria: Sector (Biotech and Pharmaceuticals), Stage of development (Market), Market Capitalization (primary ~1/3x – 3x argenx’s 30 30-day average market value as of 5/20/22, secondary \$5-50B), Headcount (primary ~1/3x – 3x the midpoint of argenx’s projected FYE22 and FYE23 headcounts, secondary 300-2500 employees), Revenue (less than \$1bn revenues), Years public (less than 10 years since IPO).

Reference date: June 2022

Company Name	Company Ticker	Country of Trade
Abcam Plc	ABC	GBR
Acadia Healthcare Company, Inc.	ACHC	USA
ALK-Abelló A/S	ALK.B	DNK
Alnylam Pharmaceuticals, Inc.	ALNY	USA
Amicus Therapeutics, Inc.	FOLD	USA
Ascendis Pharma A/S	ASND	USA
BeiGene, Ltd.	6160	USA
Biohaven Pharmaceutical Holding Company Ltd.	BHVN	USA
BioMarin Pharmaceutical Inc.	BMRN	USA
BioNTech SE	BNTX	USA
Biohaven Pharmaceutical Holding Company Ltd.	BPMC	USA
CRISPR Therapeutics AG	CRSP	USA
Denali Therapeutics Inc	DNLI	USA
Evotec SE	EVT	DEU
Galapagos NV	GLPG	NLD
Genmab A/S	GMAB	DNK
Hikma Pharmaceuticals Plc	HIK	GBR
Horizon Therapeutics Public Limited Company	HZNP	USA
Idorsia Ltd	IDIA	CHE
Incyte Corporation	INCY	USA
Intellia Therapeutics, Inc.	NTLA	USA
Intra-Cellular Therapies, Inc.	ITCI	USA
Ionis Pharmaceuticals, Inc.	IONS	USA
Mirati Therapeutics, Inc.	MRTX	USA
Neurocrine Biosciences, Inc.	NBIX	USA
Recordati SpA	REC	ITA
Sarepta Therapeutics, Inc.	SRPT	USA
Seagen Inc.	SGEN	USA
Swedish Orphan Biovitrum AB	SOBI	SWE
UCB SA	UCB	BEL
uniQure N.V.	QURE	USA
Vifor Pharma AG	VIFN	CHE